Answers are grounded in this paper and cite their sources.
EGFR: epidermal growth factor receptor SDRIFE: symmetrical drug-related intertriginous and flexural exanthema INTRODUCTION Gefitinib, an epidermal growth factor receptor (EGFR) inhibitor, has been associated with several cutaneous side effects. We report a patient presenting with symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) associated with gefitinib treatment for stage IV nonesmall cell lung cancer.
No takes yet. Share an insight, caveat, or question.
Copps et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: